Coherus Announces Marketing Authorization Application to the EMA for Pegfilgrastim Biosimilar

Goodwin
Contact
LinkedIn
Facebook
X
Send
Embed

Coherus BioSciences, Inc., a global biosimilar company, is currently advancing three late-stage clinical products towards commercialization, namely CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar).

In October, we reported that the FDA accepted Coherus’s aBLA for their pegfilgrastim biosimilar CHS-1701. Today, Coherus announced the acceptance of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for CHS-1701. This marks their first submission and acceptance in Europe.

Stay tuned to Big Molecule Watch for updates on this story and more.

Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide